We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $7.48B
1-Year Est. Return 104.76%
This Fund
S&P 500
This Quarter Est. Return
+14.34%
1 Year Est. Return
+104.76%
3 Year Est. Return
+313.12%
5 Year Est. Return
+388.67%
10 Year Est. Return
+3,437.54%
AUM
$5.11B
AUM Growth
+$508M
Cap. Flow
+$108M
Cap. Flow %
2.11%
Top 10 Hldgs %
29.75%
Holding
158
New
25
Increased
53
Reduced
18
Closed
16

Top Buys

Rank Stock Value
1
ECL icon
Ecolab
ECL
+$46M
2
ANNX icon
Annexon
ANNX
+$41.6M
3
CTAS icon
Cintas
CTAS
+$41M
4
GTM
ZoomInfo Technologies
GTM
+$40.9M
5
FRLN
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
+$39.2M

Top Sells

Rank Stock Value
1
AIMT
Aimmune Therapeutics
AIMT
+$53.4M
2
LII icon
Lennox International
LII
+$42.7M
3
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$40.3M
4
SPLK
Splunk Inc
SPLK
+$39.6M
5
ZGNX
Zogenix, Inc.
ZGNX
+$32.7M

Sector Composition

Rank Sector Weight
1 Healthcare 42.1%
2 Technology 25.02%
3 Industrials 10.32%
4 Consumer Discretionary 8.24%
5 Communication Services 4.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MPWR icon
76
Monolithic Power Systems
MPWR
$56.1B
$19.8M 0.39%
+70,975
New +$18.5M
ADCT icon
77
ADC Therapeutics
ADCT
$139M
$19.1M 0.37%
580,483
+430,483
+287% +$18.6M
XPO icon
78
XPO
XPO
$20.9B
$18.6M 0.36%
636,107
– –
ISRG icon
79
Intuitive Surgical
ISRG
$133B
$17.7M 0.35%
75,000
– –
RGEN icon
80
Repligen
RGEN
$9.86B
$17.6M 0.34%
119,000
– –
NRIX icon
81
Nurix Therapeutics
NRIX
$2.58B
$17.4M 0.34%
+497,740
New +$12.5M
ETNB
82
DELISTED
89bio
ETNB
$17.3M 0.34%
675,000
+100,000
+17% +$3.17M
REGN icon
83
Regeneron Pharmaceuticals
REGN
$79.7B
$17.3M 0.34%
30,900
– –
BEPC icon
84
Brookfield Renewable
BEPC
$5.39B
$16.7M 0.33%
+427,800
New +$14.3M
PHAT icon
85
Phathom Pharmaceuticals
PHAT
$660M
$16.5M 0.32%
450,000
– –
CCXI
86
DELISTED
ChemoCentryx, Inc.
CCXI
$16.3M 0.32%
297,000
+122,000
+70% +$6.57M
JAMF
87
DELISTED
Jamf
JAMF
$16.2M 0.32%
+430,000
New +$16.1M
XLRN
88
DELISTED
Acceleron Pharma
XLRN
$16.1M 0.31%
142,900
– –
DNTH icon
89
Dianthus Therapeutics
DNTH
$5.86B
$16M 0.31%
147,478
– –
EIDX
90
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$16M 0.31%
317,417
+104,417
+49% +$4.69M
EPIX
91
DELISTED
ESSA Pharma
EPIX
$15.3M 0.3%
2,335,169
+325,000
+16% +$2.21M
XENE icon
92
Xenon Pharmaceuticals
XENE
$5.45B
$14.1M 0.28%
1,274,100
– –
LW icon
93
Lamb Weston
LW
$6.47B
$13.5M 0.26%
203,000
-5,600
-3% -$359K
ALLK
94
DELISTED
Allakos
ALLK
$13M 0.26%
160,000
– –
CHMA
95
DELISTED
Chiasma, Inc. Common Stock
CHMA
$12.9M 0.25%
3,000,326
+2,036,326
+211% +$9.75M
DCPH
96
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$12.5M 0.24%
243,000
– –
KURA icon
97
Kura Oncology
KURA
$1.01B
$12.3M 0.24%
+400,000
New +$8.83M
MKC icon
98
McCormick & Company Non-Voting
MKC
$13.4B
$12.2M 0.24%
125,200
+5,200
+4% +$509K
XNCR icon
99
Xencor
XNCR
$1.77B
$11.6M 0.23%
300,000
– –
RLAY icon
100
Relay Therapeutics
RLAY
$4.16B
$10.6M 0.21%
+250,000
New +$9.53M
2 3
4
5 6

Similar funds

S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
CCM
Check Capital Management Costa Mesa, California $7.52B AUM 15.3% 1-Year Est. Return
O
Ossiam Paris, France $7.54B AUM 50.81% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return
HPC
HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return
FPP
Findlay Park Partners London, United Kingdom $7.41B AUM 26.32% 1-Year Est. Return
RIG
RiverFront Investment Group Richmond, Virginia $7.56B AUM 23.82% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return

Eventide Asset Management's Q3 2020 Portfolio in Review

As of Q3 2020, Eventide Asset Management held 158 positions worth $5.11B, up 11% from $4.6B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Eventide Asset Management's Q3 2020 filing shows 25 new, 53 increased, 18 reduced and 16 closed positions. Its largest new stake was Ecolab: 230,000 shares worth $46M. The largest sale was Aimmune Therapeutics, an estimated $53.4M.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, down from 47% a quarter earlier, followed by Technology and Industrials.

  • Eventide Asset Management's largest Q3 2020 buy was Ecolab: 230,000 shares worth $46M.
  • Eventide Asset Management added most to Dynatrace in Q3 2020, an estimated $32.6M increase.
  • Eventide Asset Management's biggest Q3 2020 reduction was Lennox International, cutting an estimated $42.7M.
  • Eventide Asset Management fully exited Aimmune Therapeutics in Q3 2020, selling an estimated $53.4M.
  • Eventide Asset Management's ten largest holdings make up 30% of its $5.11B portfolio in Q3 2020.
  • Eventide Asset Management opened 25 new positions and closed 16 in Q3 2020.
  • Eventide Asset Management's portfolio value rose 11% quarter-over-quarter to $5.11B.

Based on Eventide Asset Management's 13F filing for Q3 2020, filed 13 Nov 2020.